- Home
- RWAY vs CAPR Comparison
RWAY vs CAPR Comparison
Compare RWAY & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RWAY
- CAPR
- Stock Information
- Founded
- RWAY 2015
- CAPR 2005
- Country
- RWAY United States
- CAPR United States
- Employees
- RWAY N/A
- CAPR N/A
- Industry
- RWAY
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RWAY
- CAPR Health Care
- Exchange
- RWAY Nasdaq
- CAPR Nasdaq
- Market Cap
- RWAY 395.5M
- CAPR 392.8M
- IPO Year
- RWAY 2021
- CAPR N/A
- Fundamental
- Price
- RWAY $9.17
- CAPR $13.89
- Analyst Decision
- RWAY Buy
- CAPR Strong Buy
- Analyst Count
- RWAY 7
- CAPR 7
- Target Price
- RWAY $11.57
- CAPR $39.29
- AVG Volume (30 Days)
- RWAY 538.4K
- CAPR 1.5M
- Earning Date
- RWAY 05-13-2025
- CAPR 05-12-2025
- Dividend Yield
- RWAY 13.15%
- CAPR N/A
- EPS Growth
- RWAY 73.09
- CAPR N/A
- EPS
- RWAY 1.89
- CAPR N/A
- Revenue
- RWAY $144,632,000.00
- CAPR $22,270,465.00
- Revenue This Year
- RWAY N/A
- CAPR $78.85
- Revenue Next Year
- RWAY N/A
- CAPR $157.99
- P/E Ratio
- RWAY $4.86
- CAPR N/A
- Revenue Growth
- RWAY N/A
- CAPR N/A
- 52 Week Low
- RWAY $8.35
- CAPR $3.52
- 52 Week High
- RWAY $13.50
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- RWAY 39.62
- CAPR 65.03
- Support Level
- RWAY $8.83
- CAPR $9.43
- Resistance Level
- RWAY $9.24
- CAPR $10.09
- Average True Range (ATR)
- RWAY 0.43
- CAPR 0.95
- MACD
- RWAY 0.02
- CAPR 0.54
- Stochastic Oscillator
- RWAY 37.02
- CAPR 96.98
About RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and Canada, with the majority of its portfolio invested in the United States.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.